Drugs in this area are judged successful if they prevent deterioration. On that measure the results albeit from a small sample are impressive
"Overall, a majority of patients (16/19 evaluable at week 12) maintained or gained vision by week 12 compared to baseline and the other 3 patients that all received combination OPT-302 + Lucentis® therapy did not lose more than 3 letters (range -2 to -3 letters). The mean gain in visual acuity overall from baseline at week 12 in treatment naïve patients who received OPT-302 + Lucentis® was 16.5 letters (n=4) and 9.5 letters in the 2 mg OPT-302 + Lucentis® dose cohort (n=2). The mean visual acuity gain from baseline at week 12 in patients who showed a sub-optimal response to prior anti-VEGF-A therapy was 4 letters with combination OPT-302 + Lucentis® (n=10 evaluable patients; mean number of prior treatment injections = 10.5, range 3 – 55)."
So what`s it worth?? OPT 302 from these results improves patients treated for VEGF A alone and I`m sure Lucentis and Opthotech will have taken note.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX
Ann: Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M |
Open | High | Low | Value | Volume |
38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 121324 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 90033 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 95009 | 0.380 |
6 | 189166 | 0.375 |
13 | 300856 | 0.370 |
4 | 11693 | 0.365 |
7 | 278244 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 75043 | 2 |
0.395 | 13157 | 1 |
0.400 | 140733 | 2 |
0.405 | 30000 | 1 |
0.410 | 98513 | 3 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |